Artery Therapeutics, Inc. (Artery) is a biotechnology company previously developing proprietary therapeutics for cardiovascular disease (CVD). Management have expanded the firm's operations to apply developed technical and metabolic know-how to addressing treatments for diabetes-generated cardiovascular disease and neurodegenerative diseases. The firm's novel - safe and effective - peptide library is derived from apolipoprotein E (ApoE) and are designed to manipulate the ABCA1 (ATP-binding cassette) transporter, thereby altering cell membrane functionality and lipid composition. The clinical candidate programs for neurodegenerative diseases and diabetes-generated cardiovascular disease are investigational new drug (IND) ready.
